Delcath Systems (OTCMKTS:DCTH) and Invivo Therapeutics (NASDAQ:NVIV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk.

Valuation & Earnings

This table compares Delcath Systems and Invivo Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Delcath Systems $3.41 million 9.80 -$19.22 million N/A N/A
Invivo Therapeutics N/A N/A -$23.42 million ($2.25) -3.60

Delcath Systems has higher revenue and earnings than Invivo Therapeutics.

Profitability

This table compares Delcath Systems and Invivo Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Delcath Systems -1,546.38% N/A -343.56%
Invivo Therapeutics N/A -91.56% -73.10%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Delcath Systems and Invivo Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Delcath Systems 0 0 0 0 N/A
Invivo Therapeutics 0 0 0 0 N/A

Insider & Institutional Ownership

4.1% of Invivo Therapeutics shares are owned by institutional investors. 4.2% of Delcath Systems shares are owned by company insiders. Comparatively, 1.5% of Invivo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Delcath Systems has a beta of 0.07, suggesting that its stock price is 93% less volatile than the S&P 500. Comparatively, Invivo Therapeutics has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500.

Delcath Systems Company Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company is developing melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. It offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.

Invivo Therapeutics Company Profile

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord. InVivo Therapeutics Holdings Corp. has research collaboration with the Q Therapeutics, Inc. for the evaluation of the combination of PLGA-PLL based Neuro-Spinal Scaffold with adult neural progenitor cells, including those from induced pluripotent stem cells. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.